M F Yuen1, P C Wu, V C Lai, J Y Lau, C L Lai. 1. Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, People's Republic of China.
Abstract
BACKGROUND: Increased expression of the proto-oncogene c-myc is a common phenomenon in hepatocellular carcinoma (HCC). The proto-oncogenes c-fos and c-jun are involved in cell cycle progression and cellular proliferation. METHODS: The objective of this study was to elucidate the mechanism of hepatocarcinogenesis with regard to the expressions of c-myc, c-fos, and c-jun. One hundred fifty biopsied HCC specimens were stained immunohistochemically for the above phenotypic markers both in tumor tissue and in adjacent nontumor tissue. RESULTS: Although the expression of c-myc was high (74%) in tumor tissue, it was significantly less compared with the expression in nontumor tissue (100%; P = 0.0002). The expression of c-myc was inversely proportional to the grade of differentiation in tumor tissue (P = 0.0108; correlation coefficient [r] = -0.244); that is, tissue with poorer histologic differentiation had a lower level of c-myc expression. There were inverse associations between the expression of c-myc and the expression of mutated p53 (P = 0.0017; r = -0.285) as well as the expression of Ki67 (P = 0.057; r = -0.147). There was significantly high expression of c-fos in tumor tissue compared with the expression in nontumor tissue (91% vs. 0%; P < 0.0001). Both the tumor tissue and the nontumor tissue had high levels of expression of c-jun (96.53% and 100%, respectively). There was a trend toward a positive association between the expression of c-fos and the expression of c-jun in tumor tissue (P = 0.07; r = 0.162). CONCLUSIONS: Because c-myc is a known inducer of wild type p53, decreased c-myc expression may lead to uncontrolled cell growth because of the lack of p53 expression that normally induces apoptosis. The coordinated expression of c-fos and c-jun in HCC may reflect the coordinated tumor cell cycle of progression and proliferation; however, future studies are required to elucidate this possibility. Copyright 2001 American Cancer Society.
BACKGROUND: Increased expression of the proto-oncogene c-myc is a common phenomenon in hepatocellular carcinoma (HCC). The proto-oncogenes c-fos and c-jun are involved in cell cycle progression and cellular proliferation. METHODS: The objective of this study was to elucidate the mechanism of hepatocarcinogenesis with regard to the expressions of c-myc, c-fos, and c-jun. One hundred fifty biopsied HCC specimens were stained immunohistochemically for the above phenotypic markers both in tumor tissue and in adjacent nontumor tissue. RESULTS: Although the expression of c-myc was high (74%) in tumor tissue, it was significantly less compared with the expression in nontumor tissue (100%; P = 0.0002). The expression of c-myc was inversely proportional to the grade of differentiation in tumor tissue (P = 0.0108; correlation coefficient [r] = -0.244); that is, tissue with poorer histologic differentiation had a lower level of c-myc expression. There were inverse associations between the expression of c-myc and the expression of mutated p53 (P = 0.0017; r = -0.285) as well as the expression of Ki67 (P = 0.057; r = -0.147). There was significantly high expression of c-fos in tumor tissue compared with the expression in nontumor tissue (91% vs. 0%; P < 0.0001). Both the tumor tissue and the nontumor tissue had high levels of expression of c-jun (96.53% and 100%, respectively). There was a trend toward a positive association between the expression of c-fos and the expression of c-jun in tumor tissue (P = 0.07; r = 0.162). CONCLUSIONS: Because c-myc is a known inducer of wild type p53, decreased c-myc expression may lead to uncontrolled cell growth because of the lack of p53 expression that normally induces apoptosis. The coordinated expression of c-fos and c-jun in HCC may reflect the coordinated tumor cell cycle of progression and proliferation; however, future studies are required to elucidate this possibility. Copyright 2001 American Cancer Society.
Authors: S J Moghaddam; E N Haghighi; S Samiee; N Shahid; A R Keramati; S Dadgar; M R Zali Journal: World J Gastroenterol Date: 2007-01-28 Impact factor: 5.742
Authors: Mark J Hoenerhoff; Arun R Pandiri; Stephanie A Lahousse; Hu-Hua Hong; Tai-Vu Ton; Tiwanda Masinde; Scott S Auerbach; Kevin Gerrish; Pierre R Bushel; Keith R Shockley; Shyamal D Peddada; Robert C Sills Journal: Toxicol Pathol Date: 2011-05-13 Impact factor: 1.902
Authors: Johanna G Miquet; Thomas Freund; Carolina S Martinez; Lorena González; María E Díaz; Giannina P Micucci; Elsa Zotta; Ravneet K Boparai; Andrzej Bartke; Daniel Turyn; Ana I Sotelo Journal: Cell Cycle Date: 2013-02-21 Impact factor: 4.534
Authors: Seon Pil Jin; Ji Hun Kim; Min A Kim; Han-Kwang Yang; Hee Eun Lee; Hye Seung Lee; Woo Ho Kim Journal: Pathol Oncol Res Date: 2007-12-25 Impact factor: 3.201
Authors: Kamaleldin E Elagib; Mang Xiao; Isa M Hussaini; Lorrie L Delehanty; Lisa A Palmer; Frederick K Racke; Michael J Birrer; Shanmugasundaram Ganapathy-Kanniappan; Ganapath Shanmugasundaram; Michael A McDevitt; Adam N Goldfarb Journal: Mol Cell Biol Date: 2004-09 Impact factor: 4.272